Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Figures corrected NBB
Corrected annual account filed for 2023.
-
Busy address KBO
39 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Temmune Therapeutics from Mechelen, company number BE0776938722, closed financial year 2025 with a result of € -2.2 million after tax. For that financial year Temmune Therapeutics recorded a gross margin of € -377,020 and equity of € 2 million. Compared with financial year 2024, the result moved from € -1.1 million to € -2.2 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 7, 2026.
€ 2 million
▼ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.2 million
▼ 100 % more loss than in 2024
Profit after tax over the fiscal year.
€ 1.5 million
▲ 172% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.3 million.
Debts at end 2025
€ 1.1 million
Loans from banks and other lenders, long and short.
€ 320,224
▼ 24% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -737,436 | € -560,686 | € -322,150 | € -377,020 | ▼ € 54,870 |
| Profit after taxes | € -744,736 | € -564,587 | € -1,107,665 | € -2,210,492 | ▼ € 1.1 million |
| Equity | € 230,264 | € 103,010 | € 2,224,357 | € 2,013,866 | ▼ 9% |
| Total debts | € 46,351 | € 94,849 | € 423,615 | € 1,420,224 | ▲ 235% |
| Cash | € 276,083 | € 134,399 | € 538,138 | € 1,463,799 | ▲ 172% |
| Retained profit | € -744,736 | € -1,309,323 | € -756,243 | € -2,333,182 | ▼ € 1.6 million |
| Bank debt | € 1,344 | € 1,344 | € 0 | € 1,100,000 | |
| Balance sheet total | € 276,615 | € 197,859 | € 2,647,972 | € 3,434,090 | ▲ 30% |
Key figures of Temmune Therapeutics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Temmune Therapeutics?
What happened at Temmune Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Participatiemaatschappij Vlaanderen NV stepped down as director. NBB
- Tomas Heyman stepped down as director. NBB
- Roderick Verhelst stepped down as director. NBB
- Keith McCullagh stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.2 million. Source: NBB ↗
- Participatiemaatschappij Vlaanderen NV became a director. NBB
- Tomas Heyman became a director. NBB
- Dirk Reyn stepped down as director. NBB
In short
From € 744,736 loss in 2022 to € 2.2 million loss in 2025.
Management
The stake of BIOQUBE FACTORY FUND I comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Temmune TherapeuticsBehind Temmune Therapeutics is LIFE of SCI BV. The shares are held by BIOQUBE FACTORY FUND I (60.4%).
Directors
According to the 2025 annual accounts
Persoon belast met dagelijks bestuur · represented by De Maeyer Joris
Also active at: Invigo Therapeutics
since 2025
Participatiemaatschappij Vlaanderen NV
Director · represented by Wilms Tobias
Also active at: VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK, Arts Gebroeders immobilière, BEDRIJVENCENTRUM VILVOORDE, BIOTECH FONDS VLAANDEREN, MAISON DE LA RADIO FLAGEY, HERTECANT FLANGES, Site-Ontwikkeling Vlaanderen, SUSTAINABLE ENERGY VENTURES +136 more
since 2025 · until 2031
Tomas Heyman
Director
since 2025 · until 2031
since 2024 · until 2025
Roderick Verhelst
Director
since 2024 · until 2030
Keith McCullagh
Director
since 2024 · until 2030
Shareholders
60.4%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kardinaal Mercierplein 2
2800 Mechelen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 39 companies are registered at this address.
All companies at this address →FRUTAROM BELGIUM
€ 2.2 million revenue · 2025
Motorola Solutions Belgium
€ 931,294 gross margin · 2025
ESKENS BENELUX
€ 276,312 gross margin · 2025
HERA
€ 477,015 gross margin · 2025
ICON Clinical Research Belgium
€ 42.5 million revenue · 2024
+34 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0776.938.722
- VAT number
- BE 0776.938.722
- Registered office
- Kardinaal Mercierplein 2, 2800 Mechelen
- Names & denominations
- Temmune Therapeutics · TemmuneTx
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 8 November 2021
- Peppol
- Active · Active since 6 May 2025
- Activities · NACE
Vervaardiging van geneesmiddelen
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Vervaardiging van overige farmaceutische producten
Overige gespecialiseerde wetenschappelijke en technische activiteiten